Boston Scientific (NYSE:BSX) Issues Q2 2025 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its second quarter 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.710-0.730 for the period, compared to the consensus EPS estimate of 0.710. The company issued revenue guidance of $4.8 billion-$4.9 billion, compared to the consensus revenue estimate of $4.9 billion. Boston Scientific also updated its FY 2025 guidance to 2.870-2.940 EPS.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Royal Bank of Canada raised their target price on shares of Boston Scientific from $116.00 to $120.00 and gave the company an “outperform” rating in a report on Thursday, April 24th. Truist Financial lifted their price objective on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a “buy” rating in a research note on Thursday, April 24th. Erste Group Bank raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, May 8th. Robert W. Baird upped their price objective on shares of Boston Scientific from $115.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, April 24th. Finally, Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. Twenty-one analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $116.00.

Boston Scientific Stock Performance

BSX opened at $99.60 on Friday. Boston Scientific has a 52-week low of $71.88 and a 52-week high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The company has a market cap of $147.35 billion, a P/E ratio of 79.68, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The firm’s 50-day moving average price is $101.03 and its 200-day moving average price is $98.68.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same period last year, the company earned $0.56 earnings per share. Boston Scientific’s revenue for the quarter was up 20.9% compared to the same quarter last year. As a group, equities analysts anticipate that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other news, SVP Vance R. Brown sold 4,826 shares of the company’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now owns 36,193 shares of the company’s stock, valued at $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,314 shares of the company’s stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the sale, the executive vice president now directly owns 22,235 shares of the company’s stock, valued at $2,269,304.10. The trade was a 43.78% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Boston Scientific

A hedge fund recently raised its stake in Boston Scientific stock. Brighton Jones LLC raised its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 0.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,376 shares of the medical equipment provider’s stock after buying an additional 226 shares during the quarter. Brighton Jones LLC’s holdings in Boston Scientific were worth $2,445,000 as of its most recent SEC filing. 89.07% of the stock is currently owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.